-- Wedbush周三发布的研究报告指出，AMC娱乐公司（AMC）凭借其在北美的高端银幕布局以及在英国和欧盟的扩张计划，有望在2026年获得更大的市场份额。 Wedbush表示，他们仍然看好AMC娱乐公司，因为该公司有望在未来几个季度受益于更加稳定的影片发行，并且继续优先偿还债务。 该券商在指出AMC娱乐公司第一季度的业绩时表示，该公司持续提升每位观众的观影收入，过去三个季度其国内每位观众的观影收入约为24美元，国际观众约为18美元，比疫情前水平高出约30%。 Wedbush表示：“我们预计，随着观影人数和每位观众的观影收入逐步恢复正常，AMC的息税折旧摊销前利润率将在未来2-5年内升至13-16%。” Wedbush维持对AMC娱乐的“跑赢大盘”评级，目标价为3美元。
Price: $1.63, Change: $+0.04, Percent Change: +2.52%
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%